FDA Plans Behind-The-Counter Drugs Meeting, Mulls “Transitional” Status
This article was originally published in The Tan Sheet
Executive Summary
FDA will discuss the idea of behind-the-counter drug sales as a possible transitional stage between Rx and OTC status when it holds a forum on the topic with stakeholders
You may also be interested in...
FDA Awaits GAO Report To Guide Behind-The-Counter Policy
The Government Accountability Office's anticipated updated report on a behind-the-counter class of drugs will help shape FDA's policy, according to Connie T. Jung, senior policy advisor for Pharmacy Affairs
Public Citizen’s Wolfe Joins FDA Advisory Committee
FDA's Drug Safety and Risk Management Advisory Committee will be a tougher venue for drug sponsors during the next four years - long-time consumer advocate Sidney Wolfe recently was named a permanent committee member
BTC Proponents Cite Pharmacists’ Role; Opponents Question Need
There is one thing agreed on by opponents and proponents of assigning drugs to behind-the-counter status, including representatives from the pharmaceutical industry, drug retailers, the pharmacy and medical professions, researchers and consumer advocates: FDA will need a long time to reach a decision on the issue, they say